Med Biogene Inc  

(Public, CVE:MBI)   Watch this stock  
Find more results for MBI
0.0600
0.0000 (0.00%)
Delayed:   1:22PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.06 - 0.06
52 week 0.04 - 0.09
Open 0.06
Vol / Avg. 129,000.00/23,631.00
Mkt cap 5.73M
P/E     -
Div/yield     -
EPS 0.00
Shares 87.58M
Beta 2.15
Inst. own     -

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets 567.33% -421.07%
Return on average equity - -
CDP Score - -

Address

598 East Kent Avenue South
VANCOUVER, BC V5X 4V6
Canada
+1-604-7328821 (Phone)
+1-604-7324801 (Fax)

Website links

Description

Med BioGene Inc. (MBI) is a Canada-based development-stage life science company. The Company is focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer. The Company is also focused on managing the license and rights to GeneFx Lung. Its test under development, which is GeneFx Lung (formerly known as LungExpress Dx) is a gene expression-based test to improve upon staging for identifying those patients with early-stage non-small-cell lung cancer (NSCLC).

Officers and directors

Iain Weir-Jones Ph.D. Chairman of the Board, Chief Executive Officer
Ibrahim Ghobrial Chief Financial Officer
Devid Diebolt Director
Terence W. Friedlander Director
Shumsheer Sidhu Director
Toby Weir-Jones Director